1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6EB64DA211193283B0025887F00270E95
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-medical-affairs-patient-engagement-amplifying-patient-voice-support-strategies?opendocument
18
19opendocument
2034.239.154.240
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Medical Affairs Patient Advocacy

Medical Affairs and Patient Engagement: Amplifying the Patient Voice and Patient Support Strategies

ID: 5730


Features:

13 Info Graphics

16 Data Graphics

270+ Metrics

10 Narratives


Pages/Slides: 37


Published: 2022


Delivery Format: Online PDF Document


 

License Options:


Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from “Medical Affairs and Patient Engagement: Amplifying the Patient Voice and Patient Support Strategies”

STUDY OVERVIEW

With patients taking an active role in the decision-making process, it is important to engage them at each stage of the product lifecycle. As a key conduit between pharma and patients, Medical Affairs groups are uniquely poised to represent the patient voice at the company.

Best Practices, LLC conducted this benchmarking research to understand Medical Affairs’ role in patient engagement. The study specifically looks at strategies to reflect the patient voice, approaches for early-stage and late-stage support, and tactics on working with advocacy groups.

Data in this study are segmented by respondents’ description of their medical team’s effectiveness with patient engagement – highly effective vs. less effective.

KEY TOPICS

  • Patient Engagement Overview
  • Strategies to Reflect Patient Voice
  • Early and Late-Stage Patient Support
  • Working with Patient Advocacy Groups

KEY METRICS

  • How effective are Medical Affairs groups at representing the patient voice?
  • How effective are various tools and strategies used by Medical Affairs groups to collect patient voice during the pre-launch and launch phase?
  • How effective are various approaches in supporting patients at the early-stage and late-stage of their disease?
  • Medical Affairs group’s working relationship with patient advocacy groups

SAMPLE KEY FINDINGS

  • Collecting Patient Voice During Launch: Outcomes data and partnering with treatment teams are most effective ways for Medical Affairs groups to collect patient voice during the early launch phases.

METHODOLOGY

Best Practices, LLC engaged 27 Medical leaders from 26 pharmaceutical and biotechnology companies in this research through a benchmarking survey instrument. Deep-dive interviews were conducted with selected benchmark partners to deliver further insights. Data in this study are segmented by respondents’ description of their medical team’s effectiveness with patient engagement – highly effective vs. less effective.

Industries Profiled:
Pharmaceutical; Biotech; Biopharmaceutical; Medical Device; Manufacturing; Consumer Products; Diagnostic; Health Care; Service; Consulting; Communications; Clinical Research; Laboratories


Companies Profiled:
AbbVie; Adaptimmune; Alexion Pharmaceuticals; ASC Therapeutics; Astellas; Baxter International; Bayer; bioMerieux; Boehringer Ingelheim; Boston Scientific; Chiesi; Daiichi Sankyo; Eisai; EVERSANA; Kyowa Kirin; MEDiSTRAVA; Merck; Merck Sharp & Dohme; NexGen Healthcare; Sanofi; Servier; Supernus; Takeda Pharmaceuticals; Teleflex; The Medicine Group; United Therapeutics

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.